Compare COO & TROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COO | TROW |
|---|---|---|
| Founded | 1980 | 1937 |
| Country | United States | United States |
| Employees | N/A | 4802 |
| Industry | Ophthalmic Goods | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5B | 19.2B |
| IPO Year | 1994 | 2000 |
| Metric | COO | TROW |
|---|---|---|
| Price | $71.40 | $89.94 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 11 | 11 |
| Target Price | $90.18 | ★ $102.09 |
| AVG Volume (30 Days) | 1.9M | ★ 2.3M |
| Earning Date | 03-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 5.77% |
| EPS Growth | N/A | ★ 0.98 |
| EPS | 0.66 | ★ 9.24 |
| Revenue | ★ $2,532,800,000.00 | $2,370,700,000.00 |
| Revenue This Year | $6.66 | $7.13 |
| Revenue Next Year | $5.20 | $2.27 |
| P/E Ratio | $108.35 | ★ $9.75 |
| Revenue Growth | 18.41 | ★ 26.65 |
| 52 Week Low | $61.78 | $77.85 |
| 52 Week High | $89.83 | $117.02 |
| Indicator | COO | TROW |
|---|---|---|
| Relative Strength Index (RSI) | 39.36 | 46.95 |
| Support Level | $70.97 | $85.22 |
| Resistance Level | $75.24 | $106.82 |
| Average True Range (ATR) | 1.73 | 1.86 |
| MACD | 0.26 | 0.60 |
| Stochastic Oscillator | 58.35 | 76.75 |
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
T. Rowe Price provides asset management services for individual and institutional investors. It offers a broad range of no-load US and international stock, hybrid, bond, and money market funds. At the end of September, the firm had $1.767 trillion in managed assets, composed of equity (50%), balanced (35%), fixed-income and money market (12%), and alternative (3%) offerings. Approximately two-thirds of managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a US-based asset manager, deriving less than 10% of its AUM from overseas.